IL22 and psoriasis: Different from the negative results of anti-IL-22 in psoriasis trials, ILV-094 seems attractive in AD therapeutics, as it improved SCORAD and neutrophils infiltration of asthma in severe AD patients in a preliminary study (243, 244) (Table 1).